CBT-I is the first-line treatment for chronic insomnia and it outperforms every supplement. Valerian and melatonin are what is left after that.
Chronic insomnia is best treated with a behavioural programme, and this is not a soft recommendation — cognitive behavioural therapy for insomnia (CBT-I) is the recommended first-line treatment in every major guideline, has stronger and more durable effects than hypnotic medication, and is available as a structured self-help programme or with a therapist. The sleep-restriction and stimulus-control components are the active ingredients and they are counter-intuitive: you spend less time in bed, not more.
Melatonin is not a sleeping pill. It is a timing signal, and it works best for circadian problems — jet lag, shift work, and delayed sleep phase — rather than for insomnia itself. For jet lag, the evidence supports taking it at the destination's bedtime for a few days. For sleep onset insomnia, the effect is small, and the doses in most trials are low (0.5-3 mg), with higher doses not clearly better. It is well tolerated; the commonest error is taking a large dose at the wrong time, which shifts the rhythm the wrong way.
Valerian has multiple trials with inconsistent results; pooled analyses find small or equivocal effects on sleep latency. It is well tolerated and it is not a benzodiazepine. Some people find it helps.
Passionflower has small trials showing improved sleep quality and, in one trial, comparable effects to a benzodiazepine at short-term follow-up. Gentle.
What actually helps insomnia, in order of evidence. Fixed wake time (which sets the rhythm and is the single most powerful behavioural lever); getting out of bed if awake for more than about 20 minutes; not napping; restricting time in bed to actual sleep time plus a small margin; no caffeine after midday; alcohol is a sedative that fragments the second half of the night, so it makes sleep worse despite feeling helpful; a cool dark room; and morning light exposure.
What is dangerous. Sedative-hypnotic drugs and alcohol together. Herbal sedatives combined with prescribed sedatives. And a person with insomnia and loud snoring, pauses in breathing, or daytime sleepiness may have sleep apnoea, which is a medical condition with cardiovascular consequences and is not treated by any herb.
Meta-Analysis2025Sleep medicine reviews
Effects of sleep hygiene education for insomnia: A systematic review and meta-analysis.
The majority of included trials (85.71 %) had a high overall risk of bias, and the remaining had "some concerns." Future work is encouraged to generate robust evidence through the development of well-designed SHE as an examined intervention for insomnia that involves process evaluation and treatment fidelity.
PubMed 40449065 ↗
Meta-Analysis2024Clinical psychology review
Network meta-analysis examining efficacy of components of cognitive behavioural therapy for insomnia.
The current results suggest that sleep restriction therapy and stimulus control therapy are the most effective components of CBT-I.
PubMed 39504928 ↗
Meta-Analysis2024Journal of affective disorders
Cognitive behavioral therapy for insomnia to treat major depressive disorder with comorbid insomnia: A systematic review and meta-analysis.
This meta-analysis indicates that CBT-I has significant effects on depressive symptoms beyond the sleep domain among people with MDD.
PubMed 39242039 ↗
Meta-Analysis2024JNCI cancer spectrum
Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis.
CBT-I is supported as a first-line treatment for insomnia in cancer survivors, with significant benefits observed across sleep and non-sleep outcomes.
PubMed 38781520 ↗
Meta-Analysis2024Sleep medicine reviews
The effect of physical exercise interventions on insomnia: A systematic review and meta-analysis.
They have a higher risk to develop mental and cardiovascular diseases.
PubMed 38749363 ↗
Meta-Analysis2024Journal of pineal research
Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review of Randomized Controlled Trials and Dose-Response Meta-Analysis.
Our results suggest that advancing the timing of administration (3 h before the desired bedtime) and increasing the administered dose (4 mg/day), as compared to the exogenous melatonin schedule most used in clinical practice (2 mg 30 min before the desired bedtime), might optimize the efficacy of exogenous melatonin in promoting sleep.
PubMed 38888087 ↗